NervGen Pharma (TSXV:NGEN) Change In Payables And Accrued Expense : C$-0.08 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Change In Payables And Accrued Expense?

NervGen Pharma's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was C$0.34 Mil. It means NervGen Pharma's Accounts Payable & Accrued Expense increased by C$0.34 Mil from Sep. 2023 to Dec. 2023 .

NervGen Pharma's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was C$-0.07 Mil. It means NervGen Pharma's Accounts Payable & Accrued Expense declined by C$0.07 Mil from Dec. 2022 to Dec. 2023 .

NervGen Pharma Change In Payables And Accrued Expense Historical Data

The historical data trend for NervGen Pharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Change In Payables And Accrued Expense Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.36

-0.17

0.32

2.32

-0.07

NervGen Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.30	-1.32	0.71	0.20	0.34

NervGen Pharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.08 Mil.

NervGen Pharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (TSXV:NGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines